Aurinia Pharmaceuticals
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell AUPH and other ETFs, options, and stocks.About AUPH
Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.
CEOPeter S. Greenleaf
CEOPeter S. Greenleaf
Employees130
Employees130
HeadquartersEdmonton, Alberta
HeadquartersEdmonton, Alberta
Founded1993
Founded1993
Employees130
Employees130
AUPH Key Statistics
Market cap1.56B
Market cap1.56B
Price-Earnings ratio27.69
Price-Earnings ratio27.69
Dividend yield—
Dividend yield—
Average volume996.06K
Average volume996.06K
High today$11.86
High today$11.86
Low today$11.63
Low today$11.63
Open price$11.75
Open price$11.75
Volume706.84K
Volume706.84K
52 Week high$13.54
52 Week high$13.54
52 Week low$6.55
52 Week low$6.55
AUPH News
Nasdaq 12h
Aurinia Pharmaceuticals Reaches Analyst Target PriceIn recent trading, shares of Aurinia Pharmaceuticals Inc (Symbol: AUPH) have crossed above the average analyst 12-month target price of $11.71, changing hands f...
Simply Wall St 6d
How Investors Are Reacting To Aurinia Pharmaceuticals Real-World Data on LUPKYNIS UseAurinia Pharmaceuticals announced that five new data posters on LUPKYNIS (voclosporin) were presented in collaboration with independent investigators at the Ame...
TipRanks 7d
Aurinia Pharmaceuticals to Present New LUPKYNIS Data at Key ConferencesElevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to...
Analyst ratings
86%
of 7 ratingsBuy
85.7%
Hold
14.3%
Sell
0%
People also own
Based on the portfolios of people who own AUPH. This list is generated using Robinhood data, and it’s not a recommendation.